Drug Trial Radar · NCT04775082
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
82
Actual
Start
Mar 4, 2021
Primary completion
Aug 1, 2023
Study completion Feb 8, 2027
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Mar 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either get liraglutide or placebo. Which treatment the participants get is decided by chance. Liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. The participant will get 1 injection every day. In addition to taking the medicine, the participants will have talks with the study staff about healthy food choices, how they can be more physically active and what can be done to help the participants to lose weight. The study will last for about 96 weeks (almost 2 years). The participants will have 18 clinic visits and 10 phone or video calls with the study doctor/staff. Participant will have blood samples taken, have 1 test to check the heart, 1 hand X-ray taken and must fill in a diary between some of the visits.
Conditions
- Obesity
Interventions
LiraglutideDrug
The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily. The dose will increase each week over 4 or 5 weeks until the final dose is reached.
PlaceboDrug
The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative Change in Body Mass Index (BMI)Time frame: Baseline (week 0), week 56
Locations
32 sites in 9 countries. Site status is shown where the registry gives one.
TMC Hlthcr Clin Res Office
Tucson, Arizona
Children's Hospital Colorado
Denver, Colorado
Solaris Clinical Research
Meridian, Idaho
Pennington Biom Res Ctr
Baton Rouge, Louisiana
Barry J. Reiner, MD LLC
Baltimore, Maryland
University of Minnesota_CPOM
Minneapolis, Minnesota
UBMD Peds-Div of Endo/Diabetes
Buffalo, New York
PriMed Clinical Research
Dayton, Ohio
UPMC Child Hosp-Pittsburgh
Pittsburgh, Pennsylvania
UZ Brussel
Brussels, Belgium
UZ Leuven - Kindergeneeskunde
Leuven, Belgium
Mamc & Lnjp
New Delhi, India
Endolife Specialty Hospitals
Guntur, Andhra Pradesh, India
Rambam MC - Department of Pediatrics A
Haifa, Israel
Schneider MC - Endrocrinology and Diabetes
Petah Tikva, Israel
Hospital Putrajaya
Putrajaya, Malaysia
University Malaya Medical Centre
Lembah Pantai, Kuala Lumpur, Malaysia
Consultorio de Endocrinología y Pediatría
Puebla City, Mexico
Hospital da Luz Lisboa, S.A.
Lisbon, Portugal
Hospital da Luz
Lisbon, Portugal
Centro Hospitalar Lisboa Norte
Lisbon, Portugal
Unidade De Santa Maria E.P.E. - Hospital de Santa Maria
Lisbon, Portugal
ULS De Santo António, E.P.E. - Hospital de Santo António
Porto, Portugal
Unidade Local de Saúde de Santo António, E.P.E
Porto, Portugal
CUF-Porto
Porto, Portugal
Hospital CUF Porto S.A.
Porto, Portugal
FSBI 'I.I. Dedov National Medical Research Center of Endocrinology' of the MH of Russia
Moscow, Russia
NSMU paediatric clinic
Novosibirsk, Russia
Samara Regional Children Clinical Hospital n.a. N.N. Ivanova
Samara, Russia
Siberian State Medical University
Tomsk, Russia
Kantonsspital Olten
Olten, Switzerland
Kinderspital Endokrinologie, Zürich
Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.